Amarin Corporation Plc Sponsored ADR Stock News

Amarin Corporation plc (NASDAQ:AMRN ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conf...

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA®/VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid (EPA) will be presented at the 60th An...

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European S...

Amarin Corporation plc (NASDAQ:AMRN ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Mark Marmur – Vice President, Corporate Communications and Investor Relations Aaron Berg – President and Chief Executive Officer Tom Reilly – Chief Financial Officer Jonathan Provoost – Executive Vice President, Chief Legal and Compliance Officer Steven Ketchum – Executive Vice P...

-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation – -- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporati...

Uncovering affordable breakthrough stocks under $10 in the portfolio can lead to high-price return opportunities. Here, the focus is on three such stocks, each demonstrating strong fundamentals that signal high upside potential.

-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA® in Europe --

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET.